Corcept Therapeutics (CORT - Get Report) dropped on the failure of a late-phase trial of its Corlux treatment for psychotic major depression. The drug didn't meet its primary endpoint, which dictated at least a 50% improvement in symptoms as measured by the Psychiatric Rating Scale Positive Symptom Subscale. Shares were sinking 11 cents, or 10.4%, to 93 cents.Omnova Solutions (OMN - Get Report) widened its first-quarter loss to $5.1 million, or 12 cents a share, from a loss of $4.3 million, or a dime a share, a year ago. Analysts polled by Thomson Financial were looking for a loss of 2 cents a share. Revenue slipped year over year to $164.8 million -- $7.2 million under the only analyst's estimate. Shares were off 18 cents, or 2.8%, to $6.17.
Tuesday's Small-Cap Winners & Losers
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts